Jefferies keeps ISTA at hold

ISTA Pharmaceuticals Inc. was maintained at its hold rating by Jefferies & Co., Inc. analyst David Windley. The price target was raised to $7.50. Positive pipeline news and Xiborm label expansion have helped revive interest in ISTA. Shares of the Irvine, Calif., pharmaceutical company were down 49 cents, or 6.15%, at $7.48 on volume of 287,664 shares versus the three-month running average of 133,980 shares. (Nasdaq: ISTA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.